Intuitive's Patents Expired. Its Installed Base Kept Growing Anyway.

A surgeon does not glance up from a da Vinci console. She is leaning into a viewer, both hands working master controls, both feet on pedals, translating tiny finger movements into the wrist of an instrument the width of a pencil, deep inside a patient she never directly touches. It takes years of cases to get fluent. And every one of those cases consumes a fistful of Intuitive's instruments - $800 to $3,600 worth per procedure⁴ - billed quietly while everyone else argues about who invented the robot. The robot was never the point. The fluency was the point, and the fluency belongs to Intuitive.

The official story is that Intuitive built a fortress out of patents and a first FDA clearance, and that when those patents expired the fortress would fall. The patents did expire. The fortress grew.

The dates everyone gets wrong, and why it doesn't matter

Start with the myth, because it's instructive. A common assumption holds that Intuitive invented robotic surgery in 2000. The da Vinci system was actually cleared by the FDA in 1997 to assist in surgery, and in July 2000 to perform it.¹ Those clearances and the patents behind them were real first-mover advantages - but they were the kind that age out. Core da Vinci patents — filed in the late 1990s and subject to a 20-year term — began expiring in the late 2010s and into the early 2020s, and the entire industry braced for the flood⁹¹⁰: cheaper hardware, fast followers, the usual story of a monopoly dissolving the moment the IP shield drops.⁸ The followers came. Medtronic launched Hugo. Johnson & Johnson built Ottava. CMR Surgical got its Versius cleared for gallbladder removal.⁷ By the textbook, this is the chapter where the incumbent's share erodes.

It didn't erode. Even after the heart of the patent-expiry window had passed, Intuitive's installed base of da Vinci systems went from 9,902 at the end of 2024 to 11,106 at the end of 2025 - and revenue climbed about 21% to roughly $10.06 billion in the same stretch.²⁵ A moat built only on patents would have leaked when the patents lapsed. This one didn't, which tells you the patents were never holding the water.

The toll booth was never the robot

Here is the structure the patent story misses. Intuitive sells a da Vinci system for somewhere between $0.7 million and $3.1 million.⁴ That capital sale is the part competitors fixate on, because it's the part they can attack on price. But the system is a razor; the procedure is the blade. Surgeons performed about 2,683,000 procedures on da Vinci systems in 2024, and each one fed Intuitive that $800-to-$3,600 stream of instruments and accessories²⁴ - plus annual service contracts of $100,000 to $225,000 per machine.⁴ Add it up and recurring revenue - instruments, accessories, service - was 84% of the company's $8.35 billion in 2024 revenue.³ The hardware is the cost of admission. The volume is the business.

This is why the share-of-market debate is a sideshow. Estimates range from nearly 60% of the global robotic surgery market by one analyst's count to above 70% of the narrower minimally invasive soft-tissue segment by another's⁶⁷ - figures that disagree because they measure different things. But notice what every estimate agrees on: a single company built decades earlier still sits at the center of the field after its patents lapsed. The moat isn't a number on a market-share chart. It's the switching cost buried in every trained pair of hands.

Isn't this just rent on being early?

The fair objection is that Intuitive is collecting rent on a head start, and that the head start is fading. There's truth in it. The company has filed successive patents on new generations - SP, Xi, da Vinci 5 - a practice critics call evergreening, a way of papering over the expiry of the originals.⁸ And the competitive pressure is real, not theoretical: 2025 was flagged as a pivotal year precisely because well-capitalized rivals with cleared systems were finally in the field.⁷ A skeptic can reasonably say the durability we're praising is just incumbency that hasn't been tested at scale yet.

But that argument quietly concedes the point. If patents were the moat, expiry would already have shown up in the numbers - and instead the installed base grew 12% in a single year while the rivals were arriving.⁵ Evergreening buys time on the hardware; it does not explain why hospitals kept choosing the older platform. The honest answer is that a surgeon trained on da Vinci, an operating room stocked with da Vinci instruments, and a hospital amortizing a da Vinci service contract do not switch because a cheaper box appeared. They switch when the new platform is meaningfully better and when retraining is worth the disruption to a workflow that already works. So far, neither condition has held. The rent is real - but it's rent on a habit, and habits in an operating room are unusually expensive to break.

The companies that survive their own patent cliffs are the ones that treated the patent as scaffolding, not structure. Intuitive's 1997 and 2000 clearances bought it a quiet decade to do the unglamorous work: place the machines, train the surgeons, embed the instruments, and turn a one-time sale into an annuity that recurs on 84 cents of every revenue dollar.¹³ By the time the rivals arrived with cheaper boxes, the contest had already moved to ground they couldn't reach. The first-mover advantage didn't last because it was protected. It lasted because Intuitive spent it on something that can't be cleared by the FDA or struck from a patent register - the muscle memory of the people holding the controls.